[{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"Tau and Alpha-synuclein vectorized antibody","moa":"Mapk tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.25,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ AbbVie"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Voyager Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Voyager Therapeutics"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Sanofi"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"AAV Capsids","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Voyager Therapeutics, Inc","amount2":0.63,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.63,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"GBA1 Gene Replacement Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AAV-based HER2 Antibody","moa":"HER2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"VCAP-102","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"VCAP-102","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Voyager Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"Voyager Therapeutics, Inc \/ Voyager Therapeutic"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"GBA1-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Voyager Therapeutics, Inc","amount2":1.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":1.75,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"AAV-based Capsid","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":1.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.75,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"VY-TAU01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Citigroup","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Citigroup"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VY-TAU01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"VY-FXN01","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.8700000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.8700000000000001,"dosageForm":"Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SOD1-ALS","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"GBA1 Gene Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VY-TAU01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Voyager Therapeutics, Inc","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"VY1706","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Voyager Therapeutics, Inc \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Voyager Therapeutics, Inc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
